Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Donowitz GR and Earnhardt KI | Azithromycin inhibition of intracellular Legionella micdadei. | 1993 | Antimicrob. Agents Chemother. | pmid:8285604 |
Strickman D et al. | In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. | 1995 | Antimicrob. Agents Chemother. | pmid:8585717 |
Rodvold KA et al. | Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. | 2003 | Antimicrob. Agents Chemother. | pmid:12878504 |
Dunne MW et al. | Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. | 2003 | Antimicrob. Agents Chemother. | pmid:12878537 |
Batt SL et al. | Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. | 2003 | Antimicrob. Agents Chemother. | pmid:12936971 |
Kohlhoff SA et al. | In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. | 2014 | Antimicrob. Agents Chemother. | pmid:25288086 |
Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
Phimda K et al. | Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. | 2007 | Antimicrob. Agents Chemother. | pmid:17638700 |
Bosnar M et al. | Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. | 2005 | Antimicrob. Agents Chemother. | pmid:15917536 |
Michot JM et al. | Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. | 2004 | Antimicrob. Agents Chemother. | pmid:15215125 |
Hoberman A and Paradise JL | Study design questions in treatment of children with acute otitis media. | 2004 | Antimicrob. Agents Chemother. | pmid:15215151 |
Wolf K and Malinverni R | Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. | 1999 | Antimicrob. Agents Chemother. | pmid:10348778 |
Ngo LY et al. | Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. | 1999 | Antimicrob. Agents Chemother. | pmid:10348786 |
Miura Y et al. | Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. | 2014 | Antimicrob. Agents Chemother. | pmid:24982089 |
Waites KB et al. | In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. | 2016 | Antimicrob. Agents Chemother. | pmid:27671057 |
Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
Unemo M et al. | First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? | 2014 | Antimicrob. Agents Chemother. | pmid:24189248 |
Li H et al. | Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. | 2014 | Antimicrob. Agents Chemother. | pmid:24189261 |
Gillis RJ et al. | Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. | 2005 | Antimicrob. Agents Chemother. | pmid:16127063 |
Navarro G et al. | Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. | 2014 | Antimicrob. Agents Chemother. | pmid:24295976 |
RÃos AM et al. | Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. | 2005 | Antimicrob. Agents Chemother. | pmid:16127085 |
Köhler T et al. | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. | 2007 | Antimicrob. Agents Chemother. | pmid:17876004 |
Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
Biedenbach DJ et al. | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. | 2010 | Antimicrob. Agents Chemother. | pmid:20625152 |
Piesman J et al. | Efficacy of an experimental azithromycin cream for prophylaxis of tick-transmitted lyme disease spirochete infection in a murine model. | 2014 | Antimicrob. Agents Chemother. | pmid:24165183 |
Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
Chisholm SA et al. | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. | 2010 | Antimicrob. Agents Chemother. | pmid:20585125 |
Fischer JH et al. | Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. | 2012 | Antimicrob. Agents Chemother. | pmid:22106226 |
Jepras RI et al. | Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. | 1997 | Antimicrob. Agents Chemother. | pmid:9303401 |
Reveneau N et al. | Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. | 2005 | Antimicrob. Agents Chemother. | pmid:15855497 |
Azoulay-Dupuis E et al. | Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. | 1991 | Antimicrob. Agents Chemother. | pmid:1656849 |
Amacher DE et al. | Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. | 1991 | Antimicrob. Agents Chemother. | pmid:1656856 |
Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
Roblin PM and Hammerschlag MR | Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. | 1998 | Antimicrob. Agents Chemother. | pmid:9449287 |
Pene Dumitrescu T et al. | Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. | 2013 | Antimicrob. Agents Chemother. | pmid:23629714 |
Amsden GW et al. | Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. | 1999 | Antimicrob. Agents Chemother. | pmid:9869584 |
Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
Critchley IA et al. | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. | 2007 | Antimicrob. Agents Chemother. | pmid:17908940 |
Salman S et al. | Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. | 2017 | Antimicrob. Agents Chemother. | pmid:28242669 |
Goswick SM and Brenner GM | Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12543653 |
Breitschwerdt EB et al. | Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs. | 1999 | Antimicrob. Agents Chemother. | pmid:10103185 |
Lai PC and Walters JD | Azithromycin kills invasive Aggregatibacter actinomycetemcomitans in gingival epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23274657 |
Sjölund Karlsson M et al. | Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. | 2013 | Antimicrob. Agents Chemother. | pmid:23274665 |
Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. | 2001 | Antimicrob. Agents Chemother. | pmid:11302832 |
Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
Soares GM et al. | Effects of azithromycin, metronidazole, amoxicillin, and metronidazole plus amoxicillin on an in vitro polymicrobial subgingival biofilm model. | 2015 | Antimicrob. Agents Chemother. | pmid:25733510 |
Parry CM et al. | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. | 2015 | Antimicrob. Agents Chemother. | pmid:25733500 |